ArticleFrontiers in oncology2026

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Darren Hargrave et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.